Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $18.51, but opened at $19.00. Pulse Biosciences shares last traded at $18.88, with a volume of 19,754 shares.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Tuesday, August 6th.
Check Out Our Latest Stock Report on PLSE
Pulse Biosciences Price Performance
Institutional Investors Weigh In On Pulse Biosciences
Hedge funds have recently made changes to their positions in the business. Rhumbline Advisers lifted its position in Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the period. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% in the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after buying an additional 2,952 shares in the last quarter. Quest Partners LLC purchased a new position in Pulse Biosciences in the second quarter valued at about $91,000. Bank of New York Mellon Corp increased its holdings in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new position in Pulse Biosciences in the first quarter valued at about $88,000. Institutional investors and hedge funds own 76.95% of the company’s stock.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
- Five stocks we like better than Pulse Biosciences
- How to Calculate Return on Investment (ROI)
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Invest in Blue Chip Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- Do ETFs Pay Dividends? What You Need to Know
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.